The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis

AIMS: Renin‐angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. Sodium‐glucose co‐transporter‐2 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Scholtes, Rosalie A., van Raalte, Daniël H., Correa‐Rotter, Ricardo, Toto, Robert D., Heerspink, Hiddo J. L., Cain, Valerie, Sjöström, C. David, Sartipy, Peter, Stefánsson, Bergur V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078964/
https://www.ncbi.nlm.nih.gov/pubmed/31742881
http://dx.doi.org/10.1111/dom.13923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078964/
https://www.ncbi.nlm.nih.gov/pubmed/31742881
http://dx.doi.org/10.1111/dom.13923

Ejemplares similares